These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 9547132)

  • 1. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.
    Rasmussen S; Hackett E; DuBoff E; Greist J; Halaris A; Koran LM; Liebowitz M; Lydiard RB; McElroy S; Mendels J; O'Connor K
    Int Clin Psychopharmacol; 1997 Nov; 12(6):309-16. PubMed ID: 9547132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.
    Greist JH; Jefferson JW; Kobak KA; Chouinard G; DuBoff E; Halaris A; Kim SW; Koran L; Liebowtiz MR; Lydiard B
    Int Clin Psychopharmacol; 1995 Jun; 10(2):57-65. PubMed ID: 7673657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies.
    Chouinard G
    Int Clin Psychopharmacol; 1992 Oct; 7 Suppl 2():37-41. PubMed ID: 1484177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
    Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
    Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
    March JS; Biederman J; Wolkow R; Safferman A; Mardekian J; Cook EH; Cutler NR; Dominguez R; Ferguson J; Muller B; Riesenberg R; Rosenthal M; Sallee FR; Wagner KD; Steiner H
    JAMA; 1998 Nov; 280(20):1752-6. PubMed ID: 9842950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.
    Greist J; Chouinard G; DuBoff E; Halaris A; Kim SW; Koran L; Liebowitz M; Lydiard RB; Rasmussen S; White K
    Arch Gen Psychiatry; 1995 Apr; 52(4):289-95. PubMed ID: 7702445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder.
    Cook EH; Wagner KD; March JS; Biederman J; Landau P; Wolkow R; Messig M
    J Am Acad Child Adolesc Psychiatry; 2001 Oct; 40(10):1175-81. PubMed ID: 11589530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
    Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
    BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
    Bergeron R; Ravindran AV; Chaput Y; Goldner E; Swinson R; van Ameringen MA; Austin C; Hadrava V
    J Clin Psychopharmacol; 2002 Apr; 22(2):148-54. PubMed ID: 11910259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
    Mowla A; Boostani S; Dastgheib SA
    J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents.
    Alderman J; Wolkow R; Fogel IM
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):117-29. PubMed ID: 16553533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
    Ninan PT; Koran LM; Kiev A; Davidson JR; Rasmussen SA; Zajecka JM; Robinson DG; Crits-Christoph P; Mandel FS; Austin C
    J Clin Psychiatry; 2006 Jan; 67(1):15-22. PubMed ID: 16426083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy.
    Alderman J; Wolkow R; Chung M; Johnston HF
    J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):386-94. PubMed ID: 9549959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder.
    Wagner KD; Cook EH; Chung H; Messig M
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S53-60. PubMed ID: 12880500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.